CRISPR Therapeutics AG - Laporan Laba Rugi (TTM)

CRISPR Therapeutics AG
CH ˙ BRSE
Laporan Laba Rugi (TTM)

Laporan Laba Rugi CRISPR Therapeutics AG menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 77 1 1 902 902 915 915 15 14 1 100 170 170 371 272 202 203 37 38 38
Change (%) -99.07 53.13 81,803.54 0.07 1.39 0.04 -98.38 -4.93 -91.50 8,268.78 69.66 -0.06 118.35 -26.80 -25.57 0.30 -81.60 0.97 1.00
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 233 269 303 354 389 442 500 547 596 572 565 554 513 518 499 485 464 431 438 421
Change (%) 15.46 12.59 16.79 9.87 13.50 13.20 9.37 9.05 -4.11 -1.18 -1.94 -7.46 0.93 -3.67 -2.79 -4.29 -7.11 1.59 -3.94
% of Revenue 301.61 37,469.68 27,549.32 39.28 43.13 48.28 54.63 3,690.16 4,232.74 47,737.48 563.68 325.79 301.65 139.43 183.50 239.68 228.71 1,154.80 1,161.93 1,105.15
Gross Operating Profit -156 -269 -302 548 513 473 415 -532 -582 -571 -465 -384 -343 -146 -227 -282 -261 -394 -400 -382
Change (%) 72.26 12.48 -281.17 -6.26 -7.80 -12.24 -228.13 9.44 -2.00 -18.54 -17.38 -10.74 -57.30 55.00 24.50 -7.58 50.76 1.65 -4.41
% of Revenue -201.61 -37,369.68 -27,449.32 60.72 56.87 51.72 45.37 -3,590.16 -4,132.74 -47,637.48 -463.68 -225.79 -201.65 -39.43 -83.50 -139.68 -128.71 -1,054.80 -1,061.93 -1,005.15
SG&A 80 86 93 100 102 100 103 102 105 102 97 90 81 76 72 72 71 73 74 74
Change (%) 7.57 8.66 6.90 2.18 -2.05 3.51 -1.47 3.24 -2.39 -5.52 -7.48 -9.73 -5.80 -5.79 0.63 -1.21 2.31 1.84 -0.76
% of Revenue 103.04 11,925.87 8,462.76 11.05 11.28 10.90 11.27 686.06 744.96 8,552.92 96.55 52.65 47.56 20.52 26.41 35.70 35.17 195.58 197.27 193.84
R&D
Change (%)
% of Revenue
OpEx 313 355 396 454 491 541 603 649 701 674 662 644 594 594 570 557 535 504 512 494
Change (%) 13.45 11.64 14.46 8.18 10.28 11.42 7.51 8.14 -3.86 -1.84 -2.75 -7.78 0.01 -3.94 -2.36 -3.89 -5.86 1.63 -3.48
% of Revenue 404.65 49,395.55 36,012.08 50.33 54.40 59.18 65.90 4,376.22 4,977.71 56,290.40 660.23 378.45 349.20 159.95 209.91 275.39 263.88 1,350.38 1,359.20 1,298.98
Operating Income -236 -354 -395 448 411 374 312 -634 -687 -673 -562 -474 -424 -223 -299 -355 -332 -467 -474 -456
Change (%) 50.38 11.56 -213.28 -8.14 -9.22 -16.45 -303.07 8.45 -2.06 -16.56 -15.67 -10.55 -47.47 34.20 18.76 -6.28 40.36 1.68 -3.83
% of Revenue -304.65 -49,295.55 -35,912.08 49.67 45.60 40.82 34.10 -4,276.22 -4,877.71 -56,190.40 -560.23 -278.45 -249.20 -59.95 -109.91 -175.39 -163.88 -1,250.38 -1,259.20 -1,198.98
Interest Expense -2
Change (%)
% of Revenue -0.17
Net Income -211 -349 -392 447 412 378 312 -633 -681 -650 -524 -416 -354 -154 -217 -266 -240 -366 -386 -468
Change (%) 65.12 12.45 -213.84 -7.77 -8.31 -17.49 -303.29 7.48 -4.51 -19.40 -20.63 -15.00 -56.55 41.36 22.41 -9.86 52.86 5.30 21.30
% of Revenue -273.10 -48,520.86 -35,630.97 49.52 45.64 41.28 34.04 -4,274.02 -4,831.79 -54,271.70 -522.67 -244.52 -207.95 -41.38 -79.91 -131.44 -118.13 -981.54 -1,023.64 -1,229.43

Source: Capital IQ

Other Listings
GB:0VRQ
US:CRSP US$ 54.86
MX:CRSP N
DE:1CG
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista